25 Years of p53 Research

  • Pierre Hainaut
  • Klas G. Wiman

Table of contents

  1. Front Matter
    Pages i-xii
  2. Harlan Robins, Gabriela Alexe, Sandra Harris, A. J. Levine
    Pages 1-25
  3. Kristine McKinney, Carol Prives
    Pages 27-51
  4. Kevin G. McLure, Michael B. Kastan
    Pages 53-71
  5. Geoffrey M. Wahl, Jayne M. Stommel, Kurt Krummel, Mark Wade
    Pages 73-113
  6. Lauren Brown, Samuel Benchimol
    Pages 115-140
  7. Shulin Wang, Wafik S. El-Deiry
    Pages 141-163
  8. Lawrence A. Donehower, Dora Bocangel, Melissa Dumble, Guillermina Lozano
    Pages 183-207
  9. Frank McKeon, Annie Yang
    Pages 209-222
  10. Olimpia Monti, Alexander Damalas, Sabrina Strano, Giovanni Blandino
    Pages 223-232
  11. Carlos P. Rubbi, Jo Milner
    Pages 233-253
  12. Hong Shi, Florence Le Calvez, Magali Olivier, Pierre Hainaut
    Pages 293-319
  13. Magali Olivier, Pierre Hainaut, Anne-Lise Børresen-Dale
    Pages 321-338
  14. Michael T. Hemann, Scott W. Lowe
    Pages 339-351
  15. Sonia Lain, David Lane
    Pages 353-376
  16. Galina Selivanova, Vladimir J. N. Bykov, Klas G. Wiman
    Pages 399-419
  17. Frank McCormick
    Pages 421-429
  18. George Klein
    Pages 431-438
  19. Back Matter
    Pages 439-446

About this book


1. Communication, awareness and access to information: Given the complexity of the field and the fact that data pertaining to each particular aspects of p53 biology or deregulation are scattered in many different publications, it is extremely difficult to access the full scale of relevant information of any specific p53-related topic. Review arcticles, despite their fundamental role in disseminating knowledge, usually focus only on general mechanisms and do not discuss in detail the many variations that can occur with respect to cell type, particular mutation type, as well as biological activation context. Books such as this one may help in this task by putting into perspective both general considerations on the p53 pathway and more specific information on various aspects of p53. In the longer term, however, open access to p53 complexity will require the development of knowledge bases accessible through the web and using simple navigation tools to guide users towards the specific information they need. Several efforts are currently being developed in that direction. They need to be strenghtened and better integrated within the rapidly growing galaxy of web-based information sources on molecular and individual variations in cancer. 2. Reference functional assays and structural analysis: Given the huge diversity of cellular and animal models for wild-type or mutant p53 functions, it will be important to set up standard, universally accepted assays to measure critical p53 protein functions.


DNA P53, Wiman, Hainaut, tumor suppressor genes, apoptosis, muta apoptosis biology cancer cancer research cancer therapy cell genes molecular biology mutagen oncogene protein regulation tumor

Editors and affiliations

  • Pierre Hainaut
    • 1
  • Klas G. Wiman
    • 2
  1. 1.International Agency for Research on Cancer, World Health OrganizationFrance
  2. 2.Cancer Center Karolinska, Karolinska InstituteSweden

Bibliographic information